Abstract:Objective To investigate the effect of intravitreal injection of Ranibizumab in patients with nonsecerative proliferative diabetic retinopathy (N-SPDR). Methods This study included 41 cases (47 eyes) of N-SPDR patients with vitreous hemorrhage in First Affiliated Hospital of Jiamusi University from February 2014 to October 2015. According to whether the patients received intravitreal injection of Ranibizumab, there were 22 cases (25 eyes) of the observation group (intravitreal injection of Ranibizumab) and 19 cases (22 eyes) of the control group (without intravitreal injection of Ranibizumab). The two groups of patients were given conventional treatment and followed up for 2 years. The best corrected visual acuity, the number of patients who received vitrectomy, and the incidences of silicone oil filling and complications in the patients undergoing vitrectomy were compared between the two groups. Results The improvement of visual acuity in the observation group was significantly better than that in the control group (P < 0.05). The vitrectomy rate of the observation group was lower than that of the control group (P < 0.05). The incidences of silicone oil filling, exfoliation, intraoperative hemorrhage and retinal breaks of the patients undergoing vitrectomy in the observation group were lower than those in the control group (P < 0.05). Conclusions For N-SPDR patients with vitreous hemorrhage, Ranibizumab vitreous injection has significant effect, can improve patients’ vision, reduce the rate of surgical treatment, and can help to reduce the incidences of complications of vitrectomy.